Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.3
Journals
JCM
Special Issues
Current and Emerging Strategies in Ischemic Stroke: Diagnosis, Treatment, and...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Current and Emerging Strategies in Ischemic Stroke: Diagnosis, Treatment, and Prevention

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 25 August 2026 | Viewed by 1171

Editors

Dr. Dougho Park

E-Mail Website
Guest Editor
1. Medical Research Institute, Pohang Stroke and Spine Hospital, Pohang 37659, Republic of Korea
2. Medical Science and Engineering, Graduate School of Convergence Science and Technology, Pohang University of Science and Technology, Pohang 37666, Republic of Korea
Interests: medical AI; epidemiology; neurorehabilitation; and clinical neurophysiology
Dr. Hyoung Seop Kim

E-Mail Website
Guest Editor
Department of Rehabilitation, Pohang Stroke and Spine Hospital, Pohang 37659, Republic of Korea
Interests: rehabilitation medicine; physical medicine
Dr. Jong Hun Kim

E-Mail
Guest Editor Assistant
1. Department of Neurology, National Health Insurance Service Ilsan Hospital, Goyang 10444, Republic of Korea
2. Department of Neurology, Korea University Ansan Hospital, Ansan 15355, Republic of Korea
Interests: neuroimaging; neurodegenerative disease

Special Issue Information

Dear Colleagues,

Ischemic stroke is a leading cause of disability and mortality worldwide. Significant advances have been made in acute management, such as thrombolysis and mechanical thrombectomy. The focus has now shifted to optimizing the entire continuum of care, from rapid diagnosis to long-term recovery. The evolution of diagnostic imaging (CT/MRI) and the integration of novel technologies, including machine learning (ML) and artificial intelligence (AI), are playing a crucial role in personalized risk assessment and therapeutic planning.

This Special Issue aims to highlight cutting-edge research across the entire spectrum of ischemic stroke care: early diagnosis, acute intervention, comprehensive secondary prevention, and rehabilitation. We seek strategies that leverage technological and clinical advancements to improve patient outcomes, with a particular emphasis on data-driven and technology-enabled solutions.

We welcome submissions of original research articles, comprehensive reviews, and meta-analyses. Areas of interest include clinical trials for new therapies, primary/secondary prevention studies, large-scale cohort data analysis, AI/ML model validation, and research on functional outcomes and neurorehabilitation techniques.

Dr. Dougho Park
Dr. Hyoung-Seop Kim
Guest Editors

Dr. Jong Hun Kim
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnosis
  • digital medicine
  • epidemiology
  • ischemic stroke
  • machine learning
  • neurorehabilitation
  • prevention
  • stroke imaging
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

16 pages, 1269 KB  
Review
Mobile Health Interventions Across the Stroke Care Continuum: A Scoping Review
by Dahyeon Koo, Seunggyun Jeong, Kyumin Jang, Younghwan Jang, Seo Yeong Bae, Soonmi Kwon and Dougho Park
J. Clin. Med. 2026, 15(11), 4121; https://doi.org/10.3390/jcm15114121 - 26 May 2026
Viewed by 662
Abstract
Stroke causes approximately 12.2 million new cases and 6.5 million deaths annually, with survivors requiring coordinated care across pre-hospital, acute, rehabilitative, and preventive phases. Mobile health (mHealth) technologies, including smartphone applications, wearable sensors, and tablet-based platforms, have shown clinical potential across these contexts, [...] Read more.
Stroke causes approximately 12.2 million new cases and 6.5 million deaths annually, with survivors requiring coordinated care across pre-hospital, acute, rehabilitative, and preventive phases. Mobile health (mHealth) technologies, including smartphone applications, wearable sensors, and tablet-based platforms, have shown clinical potential across these contexts, yet a structured mapping of their distribution across the full stroke care continuum is lacking. We searched PubMed, Scopus, and Web of Science for publications from January 2019 to March 2025. Studies evaluated mHealth interventions in which the mobile platform directly performed diagnostic, therapeutic, or rehabilitative functions in stroke populations. Of 4524 records identified, 17 met the inclusion criteria. Studies originated from eight countries and used heterogeneous designs: five randomized controlled trials, five non-randomized studies, four cohort studies, and three diagnostic accuracy studies. Median sample size was 37 participants (range 10–2249). Evidence concentrated at two poles: six studies addressed acute diagnosis and ten addressed rehabilitation, predominantly in the chronic phase. One study addressed secondary prevention; two targeted early rehabilitation, the period of maximum neuroplasticity after discharge. All seventeen studies covered a single care phase. Smartphone platforms dominated acute contexts; wearable and mixed-modality systems were confined to rehabilitation. The mHealth stroke landscape is fragmented and phase-specific, exhibiting a silo effect in which interventions operate as isolated tools rather than components of an integrated care system. An important gap is the near-absence of research in early rehabilitation. Future priorities include cross-continuum design, expansion into cognitive and secondary prevention domains, and progression toward adequately powered trials. Full article
(This article belongs to the Special Issue Current and Emerging Strategies in Ischemic Stroke: Diagnosis, Treatment, and Prevention)
►▼ Show Figures

Figure 1

Other

Jump to: Review

20 pages, 7811 KB  
Systematic Review
Clinical Outcomes of Early Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in East Asian Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
by Sarah Alqhtani, Hannah Abid, Montaha Almatrafi, Amal Bamehriz, Shatha Alqurashi, Ahmed Alkhiri, Norah Alqhtani, Gadi Sindi, Kamal Bin Salama, Faris Alzahrani and Adel Alhazzani
J. Clin. Med. 2026, 15(13), 5169; https://doi.org/10.3390/jcm15135169 - 2 Jul 2026
Viewed by 123
Abstract
Background: Dyslipidemia is a modifiable risk factor and predictive biomarker for acute ischemic stroke (AIS) that necessitates early, aggressive lipid-lowering therapy to achieve target low-density lipoprotein cholesterol (LDL-C) levels for primary and secondary prevention. In certain patients, this can be difficult to achieve [...] Read more.
Background: Dyslipidemia is a modifiable risk factor and predictive biomarker for acute ischemic stroke (AIS) that necessitates early, aggressive lipid-lowering therapy to achieve target low-density lipoprotein cholesterol (LDL-C) levels for primary and secondary prevention. In certain patients, this can be difficult to achieve with statins alone. Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) lipid-lowering agents may improve outcomes when introduced early. This review assessed whether early PCSK9i administration (within 3 weeks of AIS) reduced early neurological deterioration (END), recurrent stroke/transient ischemic attack (TIA), poor functional outcomes, and mortality. Methods: This systematic review and meta-analysis included randomized clinical trials (RCTs) and observational studies. Random-effects meta-analysis and subgroup and sensitivity analyses were used to assess whether effects differed by treatment timing (≤72 vs. >72 h) and study design. Results: Eight studies (three randomized clinical trials) in East Asian cohorts were included. Early PCSK9i initiation significantly reduced END compared with usual care (odds ratio [OR]: 0.39; 95% confidence interval [CI]: 0.26–0.57). Stroke/TIA recurrence and all-cause mortality within 6 months of stroke were also significantly reduced in the PCSK9i group (OR: 0.47; 95% CI: 0.28–0.77 and OR: 0.33; 95% CI: 0.15–0.72, respectively), and early initiation was associated with a greater likelihood of good functional outcomes at 90 days (OR: 2.28; 95% CI: 1.48–3.51). Sensitivity analyses yielded consistent results. Conclusions: Early PCSK9i initiation within 3 weeks of AIS onset was associated with lower rates of END, recurrent stroke/TIA, and mortality, although the certainty of evidence was limited by the small number of included studies and the predominantly observational data. Outcomes did not differ significantly by initiation timing within this period. Large-scale trials in diverse populations are needed to define the optimal initiation window and long-term clinical effects. Full article
(This article belongs to the Special Issue Current and Emerging Strategies in Ischemic Stroke: Diagnosis, Treatment, and Prevention)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop